Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The daily Top 10 COVID papers


  Influenza

  Free Subscription


Articles published in Antimicrob Agents Chemother

Retrieve available abstracts of 43 articles:
HTML format



Single Articles


    December 2020
  1. ALEISSA MM, Silverman EA, Paredes Acosta LM, Nutt CT, et al
    New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.
    Antimicrob Agents Chemother. 2020;65.
    PubMed     Abstract available


  2. VANDERLINDEN E, Van Winkel N, Naesens L, Van Damme EJM, et al
    In Vitro Characterization of the Carbohydrate-Binding Agents HHA, GNA and UDA as Inhibitors of Influenza a and B Virus Replication.
    Antimicrob Agents Chemother. 2020 Dec 7. pii: AAC.01732.
    PubMed     Abstract available


    November 2020
  3. SUZUKI S, Nguyen CT, Ogata-Nakahara A, Shibata A, et al
    Efficacy of a cap-dependent endonuclease inhibitor and neuraminidase inhibitors against H7N9 highly pathogenic avian influenza virus causing severe viral pneumonia in cynomolgus macaques.
    Antimicrob Agents Chemother. 2020 Nov 30. pii: AAC.01825.
    PubMed     Abstract available


  4. MCCULLOUGH PA
    Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


  5. YAN VC, Muller FL
    Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity.
    Antimicrob Agents Chemother. 2020;64.
    PubMed    


  6. LE MP, Le Beller C, Le Hingrat Q, Jaquet P, et al
    Reply to Yan and Muller, "Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity".
    Antimicrob Agents Chemother. 2020;64.
    PubMed    


  7. DOI Y, Hibino M, Hase R, Yamamoto M, et al
    A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


    October 2020
  8. LE MP, Le Hingrat Q, Jaquet P, Wicky PH, et al
    Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


  9. BUEHRLE DJ, Decker BK, Wagener MM, Adalja A, et al
    Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 2019 Epicenter.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


    August 2020
  10. FERNANDEZ-CRUZ A, Ruiz-Antoran B, Munoz-Gomez A, Sancho-Lopez A, et al
    A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


  11. FINTELMAN-RODRIGUES N, Sacramento CQ, Ribeiro Lima C, Souza da Silva F, et al
    Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production.
    Antimicrob Agents Chemother. 2020 Aug 5. pii: AAC.00825.
    PubMed     Abstract available


    July 2020
  12. GORDY JT, Mazumdar K, Dutta NK
    Accelerating Drug Development through Repurposed FDA-Approved Drugs for COVID-19: Speed Is Important, Not Haste.
    Antimicrob Agents Chemother. 2020;64.
    PubMed    


  13. DANION F, Ruch Y, Fourtage M, Kaeuffer C, et al
    The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    PubMed    


  14. SALGADO-BENVINDO C, Thaler M, Tas A, Ogando NS, et al
    Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


  15. DAVOUDI-MONFARED E, Rahmani H, Khalili H, Hajiabdolbaghi M, et al
    Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial.
    Antimicrob Agents Chemother. 2020 Jul 13. pii: AAC.01061.
    PubMed     Abstract available


  16. MARZOLINI C, Stader F, Stoeckle M, Franzeck F, et al
    Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
    Antimicrob Agents Chemother. 2020 Jul 8. pii: AAC.01177.
    PubMed     Abstract available


  17. MARATHE BM, Asthagiri Arunkumar G, Vogel P, Pascua PNQ, et al
    Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.00284.
    PubMed     Abstract available


  18. MARTINEZ MA
    Clinical trials of repurposed antivirals for SARS-CoV-2.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.01101.
    PubMed     Abstract available


    June 2020
  19. SOFTIC L, Brillet R, Berry F, Ahnou N, et al
    Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


  20. JEON S, Ko M, Lee J, Choi I, et al
    Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


    May 2020
  21. HOFFMANN M, Schroeder S, Kleine-Weber H, Muller MA, et al
    Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    PubMed    


  22. LI H, Zhou Y, Zhang M, Wang H, et al
    Updated Approaches against SARS-CoV-2.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


  23. LIM JJ, Nilsson AC, Silverman M, Assy N, et al
    A phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza A infection.
    Antimicrob Agents Chemother. 2020 May 11. pii: AAC.00352.
    PubMed     Abstract available


  24. ADAMS SE, Lugovtsev VY, Kan A, Bovin NV, et al
    Laninamivir-Interferon-lambda1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly Than Laninamivir Alone.
    Antimicrob Agents Chemother. 2020 May 11. pii: AAC.00301.
    PubMed     Abstract available


    April 2020
  25. KOSHIMICHI H, Retout S, Cosson V, Duval V, et al
    Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Patients Infected with Influenza at High Risk of Influenza Complications.
    Antimicrob Agents Chemother. 2020 Apr 20. pii: AAC.00119.
    PubMed     Abstract available


  26. ZHAO L, Yan Y, Dai Q, Li X, et al
    Development of Novel Anti-influenza Thiazolides with Relatively Broad-spectrum Antiviral Potentials.
    Antimicrob Agents Chemother. 2020 Apr 20. pii: AAC.00222.
    PubMed     Abstract available


  27. NGUYEN CT, Suzuki S, Itoh Y, Ishigaki H, et al
    Efficacy of neuraminidase inhibitors against H5N6 highly pathogenic avian influenza virus in a non-human primate model.
    Antimicrob Agents Chemother. 2020 Apr 13. pii: AAC.02561.
    PubMed     Abstract available


    March 2020
  28. MARTINEZ MA
    Compounds with therapeutic potential against novel respiratory 2019 coronavirus.
    Antimicrob Agents Chemother. 2020 Mar 9. pii: AAC.00399.
    PubMed     Abstract available


    January 2020
  29. BROADBENT L, Parke HG, Ferguson LJ, Millar A, et al
    Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


  30. DEVINCENZO J, Tait D, Efthimiou J, Mori J, et al
    A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


    September 2018
  31. FARRUKEE R, Zarebski AE, McCaw JM, Bloom JD, et al
    CHARACTERIZATION OF INFLUENZA B VIRUS VARIANTS WITH REDUCED NEURAMINIDASE INHIBITOR SUSCEPTIBILITY.
    Antimicrob Agents Chemother. 2018 Sep 10. pii: AAC.01081.
    PubMed     Abstract available


    August 2018
  32. ALI SO, Takas T, Nyborg A, Shoemaker K, et al
    Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
    Antimicrob Agents Chemother. 2018 Aug 27. pii: AAC.00694.
    PubMed     Abstract available


    June 2018
  33. YOON JJ, Toots M, Lee S, Lee ME, et al
    Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.
    Antimicrob Agents Chemother. 2018 Jun 11. pii: AAC.00766.
    PubMed     Abstract available


    March 2018
  34. VIGIL A, Estelles A, Kauvar LM, Johnson SK, et al
    Native human monoclonal antibodies with potent cross-lineage neutralization of influenza B viruses.
    Antimicrob Agents Chemother. 2018 Mar 5. pii: AAC.02269.
    PubMed     Abstract available


    January 2018
  35. MCBRIDE JM, Lim JJ, Burgess T, Deng R, et al
    Reply to Hunsberger and Memoli, "Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat".
    Antimicrob Agents Chemother. 2017;62.
    PubMed    


  36. HUNSBERGER S, Memoli MJ
    Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat.
    Antimicrob Agents Chemother. 2017;62.
    PubMed    


    November 2017
  37. TSUJI BT, Fisher J, Boadi-Yeboah R, Holden PN, et al
    Azithromycin Pharmacodynamics against 'Persistent' Haemophilus influenza in Chronic Obstructive Pulmonary Disease.
    Antimicrob Agents Chemother. 2017 Nov 27. pii: AAC.01995.
    PubMed     Abstract available


    August 2017
  38. MCBRIDE JM, Lim JJ, Burgess T, Deng R, et al
    Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Challenge Model: A Phase 2 Randomized Trial.
    Antimicrob Agents Chemother. 2017 Aug 14. pii: AAC.01154.
    PubMed     Abstract available


    May 2017
  39. LIM JJ, Derby MA, Zhang Y, Deng R, et al
    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Monoclonal Antibody, MHAB5553A, in Healthy Volunteers.
    Antimicrob Agents Chemother. 2017 May 30. pii: AAC.00279.
    PubMed     Abstract available


    April 2017
  40. STAROSILA D, Rybalko S, Varbanetz L, Ivanskaya N, et al
    Anti-influenza activity of Bacillus subtilis probiotic strain.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.00539.
    PubMed     Abstract available


  41. GAILLARD V, Galloux M, Garcin D, Eleouet JF, et al
    A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Abstract available


    March 2017
  42. GRIFFIN MP, Khan AA, Esser MT, Jensen K, et al
    Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Abstract available


    February 2017
  43. JONES JC, Marathe BM, Vogel P, Gasser R, et al
    The PA endonuclease inhibitor RO-7 protects mice from lethal challenge with influenza A or B viruses.
    Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.02460.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: